Budd-Chiari syndrome and portal vein thrombosis are uncommon but diagnostically challenging — each caused most often by underlying thrombophilia, each with stepwise management from anticoagulation through TIPS to transplantation.
Identify the clinical presentations of Budd-Chiari syndrome, portal vein thrombosis, and sinusoidal obstruction syndrome
Interpret Doppler ultrasound findings and explain their significance in hepatic vascular disease
Apply anticoagulation principles and delineate the stepwise management from medical therapy through TIPS to transplantation
38 min · 9 sectionsCore Disease
Reading mode
On this page
01BCS — Definition
02BCS — Etiology
03BCS — Diagnosis
04BCS — Management
05PVT — Definition
06PVT — Etiology
07PVT — Diagnosis
08PVT — Management
09Clinical Case
Progress0/9
Budd-Chiari Syndrome (BCS) is defined as obstruction of hepatic venous outflow at any level — from the small hepatic venules to the junction of the hepatic veins with the inferior vena cava (IVC). Cardiac causes of hepatic venous congestion (constrictive pericarditis, right heart failure) are excluded by definition; these are classified separately as cardiac hepatopathy.
Two different levels: PVT blocks venous inflow, Budd-Chiari blocks outflow. The caudate's direct IVC drainage is why it hypertrophies in BCS.
The classic triad of abdominal pain, hepatomegaly, and ascites is present in only ~20% of patients at presentation1 — the majority present with an incomplete picture or are identified during workup for unexplained ascites or an incidental imaging finding.
Form
Timeframe
Clinical Features
Hyperacute
<1 week
Severe abdominal pain, rapidly progressive liver failure; may mimic acute hepatitis or ischemic hepatitis
Acute
1–4 weeks
Abdominal pain, hepatomegaly, ascites, coagulopathy; no established collaterals yet
Subacute
1–6 months
Insidious onset; ascites dominates; some hepatic collateral development; may be misdiagnosed as chronic liver disease
Chronic
>6 months
Established collaterals, caudate hypertrophy, progressive fibrosis or cirrhosis; portal hypertension features predominate
Quick recall
1/3
A 31-year-old woman on oral contraceptives presents with 3 weeks of RUQ discomfort, new ascites, and splenomegaly. ALT is mildly elevated. No prior liver disease. What diagnosis must you exclude, and what is the first investigation?
Tap to reveal →
An underlying prothrombotic condition is identified in >75% of BCS patients1. A comprehensive thrombophilia evaluation must be performed in all patients — importantly, multiple concurrent risk factors are present in approximately 25%2 of cases, making a single identified etiology insufficient to stop the workup.
Most common etiology. JAK2 V617F mutation in ~40–50% of all BCS patients.¹ Test all patients even without overt MPN features — occult MPN is common and may be unmasked only by the thrombotic event.
Factor V Leiden
Activated protein C resistance
Second most common systemic thrombophilia; test for both heterozygous and homozygous mutations. Additive risk when combined with OCPs or pregnancy.
Antiphospholipid syndrome (APS)
Test: anticardiolipin IgG/IgM, anti-β2-glycoprotein I, lupus anticoagulant. Note: lupus anticoagulant assay requires the patient to be off anticoagulation and should be repeated for confirmation 12 weeks apart.
Paroxysmal nocturnal hemoglobinuria (PNH)
Diagnosis by flow cytometry for GPI-anchored proteins (CD55, CD59) on red blood cells and neutrophils. An underrecognized cause; eculizumab is disease-modifying therapy.
Protein C, Protein S, Antithrombin III deficiency
Testing caveat: Levels are unreliable during acute thrombosis and on anticoagulation. Also reduced by acute liver disease. Test after clinical stabilization — ideally after transition to stable warfarin therapy or after resolution of the acute event.
Prothrombin gene mutation (G20210A)
Causes elevated prothrombin levels and increased thrombin generation. Identified by PCR-based genotyping.
Oral contraceptive pills (OCPs)
Additive risk when combined with inherited thrombophilias (e.g., Factor V Leiden + OCP = markedly elevated risk). Counsel on discontinuation.
Pregnancy and postpartum
Hypercoagulable state of pregnancy may unmask underlying thrombophilia. BCS presenting peripartum should trigger full thrombophilia evaluation after delivery.
Key Pearl — Multiple Concurrent Conditions
Multiple concurrent conditions in 25% of patients. A complete thrombophilia panel — including JAK2 mutation, APS panel, Factor V Leiden, prothrombin G20210A, protein C/S/AT-III, PNH by flow cytometry — should be sent in every BCS patient. Identifying a first etiology does not end the search.
Quick recall
1/3
What is the most common thrombophilia underlying Budd-Chiari Syndrome?
Absent or reversed flow in hepatic veins; echogenic thrombus may be visible within veins
Spiderweb pattern of intrahepatic venous collaterals — pathognomonic when present
Caudate lobe hypertrophy — the caudate has independent venous drainage directly to the IVC and therefore preferentially hypertrophies when the other hepatic veins are obstructed
Ascites; compressed or absent IVC in IVC-level obstruction
Sensitivity ~75%; a negative Doppler USS does not exclude BCS — always follow with cross-sectional imaging if clinical suspicion remains
CT or MRI Venography — Confirmatory Imaging
Defines the precise level and extent of obstruction (hepatic veins only vs. IVC involvement vs. both)
CT triple-phase: Early caudate lobe enhancement (relative to rest of liver); peripheral heterogeneous enhancement or mottling; intrahepatic venous collaterals; IVC thrombus or extrinsic compression
MRI: Comma-shaped or dilated caudate lobe; intrahepatic collaterals; heterogeneous parenchymal signal; useful when iodinated contrast is contraindicated
MR or CT venography provides roadmap for endovascular planning
Liver biopsy: Not required for diagnosis. Histology shows centrilobular congestion, sinusoidal dilation, and hepatocyte necrosis in acute BCS; progressive perivenular fibrosis in chronic BCS. Reserve biopsy for cases where diagnosis remains uncertain after imaging.
Quick recall
1/3
What is the pathognomonic Doppler USS finding in Budd-Chiari Syndrome?
Tap to reveal →
Management follows a stepwise escalation: anticoagulation first in all patients, endovascular intervention for those who fail anticoagulation alone, and liver transplantation for those who develop cirrhosis or acute liver failure.
Step 1 — Anticoagulation (all patients)
Initiate therapeutic LMWH immediately in all patients regardless of acuity — prevents thrombus propagation and supports recanalization. Bridge with LMWH; transition to warfarin targeting INR 2–3. DOACs increasingly used based on case series data; no RCT data specific to BCS yet. Treat underlying thrombophilia concurrently: hydroxyurea or ruxolitinib for MPN, eculizumab for PNH. Anticoagulation is lifelong in virtually all patients given high recurrence risk.
For patients with persistent clinical deterioration, refractory ascites, or worsening hepatic function despite adequate anticoagulation. Angioplasty ± stenting: effective for short-segment IVC or hepatic vein stenosis (membranous or web obstruction). TIPS: creates a direct portal-to-hepatic vein channel bypassing the obstruction; technical success ~95% in experienced centers.¹ Monitor closely for hepatic encephalopathy (HE) post-TIPS.
If refractory
Step 3 — Liver Transplantation (cirrhosis or ALF)
Indicated for chronic BCS progressing to cirrhosis with portal hypertension, or BCS-related acute liver failure not responding to steps 1–2. Post-transplant anticoagulation is lifelong — the underlying thrombophilia persists after transplantation. Excellent outcomes: 5-year survival >70% in contemporary series. Exception points on MELD may be available at some centers for BCS with progressive disease.
If needed
0 of 3 complete
Quick recall
1/3
What is the first step in BCS management regardless of disease acuity?
Tap to reveal →
Portal Vein Thrombosis (PVT) is occlusion of the portal vein and/or its tributaries — splenic vein, superior mesenteric vein (SMV) — by thrombus. Classification is multidimensional and determines prognosis and management approach.
Dimension
Categories
Clinical Significance
Acuity
Acute (≤60 days) vs. Chronic (cavernous transformation)
Acute PVT presents with abdominal pain, fever; chronic PVT is often incidental. Recanalization is achievable in acute but not in established cavernous transformation.
Extent
Portal vein alone vs. SMV/splenic vein involvement; partial vs. complete occlusion
Extensive SMV thrombosis raises risk of intestinal ischemia — a surgical emergency. Partial occlusion has higher recanalization rates than complete.
Context
Cirrhotic PVT vs. Non-cirrhotic PVT
Cirrhotic PVT occurs in 10–25% of cirrhotics awaiting transplant; management approach and anticoagulation decision-making differ significantly from non-cirrhotic PVT.
Cavernous Transformation
Cavernous transformation refers to the development of collateral venous channels around a chronically thrombosed and recanalized portal vein, creating a characteristic "mass" of small vessels on imaging. It signals long-standing PVT (>several weeks to months). Clinically important: the native portal vein may no longer be usable for the portal anastomosis in liver transplantation, substantially increasing operative complexity and risk.
Quick recall
1/3
What is cavernous transformation of the portal vein and why does it matter for transplant?
Tap to reveal →
Cirrhotic PVT — Pathophysiology
Slow portal blood flow — low portal flow velocity in portal hypertension predisposes to in situ thrombosis (Virchow's triad: stasis)
Endothelial dysfunction — local inflammation and endothelial activation in advanced cirrhosis
Prothrombotic imbalance — reduced anticoagulant proteins (protein C, protein S) with preserved or elevated procoagulant factors (factor VIII); INR does not reflect the full coagulation picture in cirrhosis
PVT prevalence increases with HVPG severity1 — higher portal pressure correlates with lower portal flow velocity and higher thrombosis risk
Always rule out HCC with portal vein invasion (tumor thrombus) before attributing PVT to cirrhosis alone
Non-Cirrhotic PVT — Systemic and Local Causes
Systemic thrombophilias — same panel as BCS: JAK2 V617F (MPN), Factor V Leiden, antiphospholipid syndrome, antithrombin III deficiency, prothrombin G20210A, protein C/S deficiency, PNH
Pancreatitis — splenic vein thrombosis (left-sided/sinistral portal hypertension) is the classic complication; may extend to portal vein
Inflammatory bowel disease (IBD) — hypercoagulable state; particularly Crohn's disease with active inflammation
Pylephlebitis — septic PVT from portal vein seeding secondary to intra-abdominal infection (diverticulitis, appendicitis, perforated viscus); presents with fever and bacteremia alongside PVT
Abdominal surgery or trauma — postoperative state, splenectomy, abdominal trauma
HCC with portal vein invasion — tumor thrombus vs. bland thrombus: critical distinction (see Diagnosis section)
Quick recall
1/3
Why does INR underestimate the true coagulation status in cirrhotic PVT?
Tap to reveal →
Imaging Approach
Doppler ultrasound (first-line): Identifies echogenic material within the portal vein; absent Doppler flow signal; cavernous transformation in chronic PVT (tangles of small collateral channels). Widely available and non-invasive.
CT with contrast — triple-phase (standard for characterization): Defines the full extent of thrombosis (portal vein, SMV, splenic vein involvement); characterizes the thrombus; differentiates tumor thrombus from bland thrombus based on enhancement pattern.
MRI: Alternative when iodinated contrast is contraindicated; useful for soft tissue characterization and when MR angiography is needed for transplant planning.
Tumor Thrombus vs. Bland Thrombus — Critical Distinction in HCC
Tumor thrombus: Arterial hyperenhancement within the thrombus on CT or MRI (the tumor supplies its own blood and enhances on arterial phase) — this is the defining feature. The thrombus "lights up" on arterial phase imaging.
Bland thrombus: No arterial enhancement; filling defect without internal vascularity
A markedly elevated AFP strongly supports HCC tumor thrombus in a cirrhotic patient with PVT
Treatment implications differ significantly: Tumor thrombus indicates advanced HCC (BCLC stage C); treatment is sorafenib or lenvatinib — not anticoagulation. Anticoagulation is the treatment for bland thrombus. Misidentification can lead to delay in appropriate oncologic therapy or inappropriate anticoagulation in a patient with vascular tumor invasion.
Quick recall
1/3
What imaging feature distinguishes HCC tumor thrombus from bland thrombus on CT?
Tap to reveal →
Non-Cirrhotic Acute PVT
Anticoagulate Immediately
Therapeutic anticoagulation in all non-cirrhotic acute PVT — LMWH or DOACs
Primary goals: recanalization and prevention of intestinal ischemia in extensive SMV thrombosis
Recanalization rates ~50–70% with early anticoagulation¹; higher with earlier initiation
Duration: minimum 3–6 months; indefinite if underlying thrombophilia identified
Pylephlebitis (septic PVT): treat underlying infection (IV antibiotics) concurrently; anticoagulation still appropriate in most cases
Cirrhotic PVT
Anticoagulation Increasingly Supported
Supported per AASLD 2020 guidance and multiple retrospective and prospective studies
Preferred agents: LMWH or apixaban; warfarin less predictable in cirrhosis
Perform EGD first to rule out high-risk varices; band ligation if needed before starting
Recanalization improves outcomes and simplifies transplant surgery
Benefit clearest for acute and subacute PVT; chronic cavernous transformation unlikely to recanalize
Treat and achieve recanalization before transplant listing when possible
Mandatory: rule out HCC (CT or MRI; AFP) before attributing PVT to cirrhosis
Chronic Non-Cirrhotic PVT
Cavernous Transformation
If underlying thrombophilia identified: indefinite anticoagulation to prevent extension and new thrombotic events
Portal biliopathy: compression of bile duct by cavernoma — may present as biliary stricture, cholestasis, cholangitis; requires ERCP ± stenting for symptomatic cases
No established role for TIPS in non-cirrhotic chronic PVT — anatomy frequently prohibitive
Surgical portosystemic shunts occasionally considered at specialized centers
Recanalization generally not achievable once cavernous transformation is established
DOAC Evidence in Cirrhosis
Emerging Evidence for DOACs in Cirrhotic PVT
Multiple retrospective series and prospective studies including the PILOT trial (rivaroxaban) and case series evaluating apixaban have demonstrated DOAC safety in Child-Pugh A/B cirrhosis. Key findings:
DOACs demonstrated acceptable safety and efficacy in Child-Pugh A and B cirrhosis — bleeding rates were not significantly higher than LMWH in most series
Avoid in Child-Pugh C decompensated cirrhosis — limited data, high baseline bleeding risk (severe coagulopathy, thrombocytopenia), and concerns about renal clearance in hepatorenal physiology
Apixaban is preferred in Child-Pugh B — minimal renal dependence for elimination makes it more predictable than rivaroxaban in patients with early renal dysfunction common in advanced cirrhosis
DOACs cannot be reliably monitored by standard coagulation tests in cirrhosis; anti-Xa levels (for apixaban/rivaroxaban) can be obtained if direct measurement is needed
Quick recall
1/3
A cirrhotic patient being evaluated for liver transplantation has incidental non-occlusive PVT extending into the proximal SMV on CT. How does this affect transplant evaluation, and what is the first management step?
Tap to reveal →
Clinical Case Vignette
A 35-year-old woman on combined oral contraceptive pills presents with acute epigastric pain of 5 days' duration, progressive abdominal distension, and low-grade fever. Examination reveals hepatomegaly and tense ascites. No prior liver disease.
Doppler ultrasound: Absent hepatic vein flow bilaterally; spiderweb pattern of intrahepatic collaterals; caudate lobe hypertrophy; moderate ascites. CT venography: Occlusion of all three major hepatic veins at their ostia with no IVC involvement. Thrombophilia workup: JAK2 V617F mutation (positive); anticardiolipin IgG elevated ×2 on repeated testing 12 weeks apart; lupus anticoagulant positive — two concurrent thrombophilic conditions.
Work through the management step by step before the answers are revealed.
References
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366-413. PubMed 33219529
DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study of Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49(5):1729-1764. PubMed 19399912
European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179-202. PubMed 26516032
Hernández-Gea V, De Gottardi A, Leebeek FWG, et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. J Hepatol. 2019;71(1):175-199. PubMed 30822449